Evaluation of the Pharmacokinetics, Bioequivalence, and Safety of Two Preparations of 20‐mg Trimetazidine in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2025-11 · 14 (11) · 889-896
DOI: 10.1002/cpdd.1582 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 06.08.2025. Verfasst von Dongmei Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Trimetazidine, Vasodilator Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
In this study, we assessed the pharmacokinetics, safety, and bioequivalence of trimetazidine tablets from 2 different manufacturers in healthy Chinese individuals under both fasting and fed conditions. Twenty‐eight healthy Chinese volunteers were included in each fasting and fed group. They were randomly assigned to fasting and fed arms in a single‐center, randomized, open‐label, crossover trial with a 2‐period, 2‐sequence design. Plasma trimetazidine levels were determined using liquid chromatography‐tandem mass spectrometry. Pharmacokinetic parameters were determined using a nonatrioventricular model. The pharmacokinetic parameters were obtained by the concentration‐time profiles, including the area under the plasma concentration‐time curve from time 0 to 24 hours, area under the concentration‐time curve from time 0 to infinity, maximum concentration, time to achieve maximum concentration, and elimination half‐life. Both trimetazidine preparations were bioequivalent under fasting and fed states, with all parameters within the acceptable limits. All recorded adverse events were mild. Overall, the test trimetazidine formulation was bioequivalent to the reference formulation and safe for use in healthy Chinese subjects in both the fasting and fed states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
- Infection Medicine Research Institute of Panyu District, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Tan, D., Zhang, F., Fu, X., Su, J., Xu, Z., Yang, H., & Mu, Y. (2025). Evaluation of the Pharmacokinetics, Bioequivalence, and Safety of Two Preparations of 20‐mg Trimetazidine in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 14(11), 889-896. https://doi.org/10.1002/cpdd.1582
Vancouver
Tan D, Zhang F, Fu X, Su J, Xu Z, Yang H, et al. Evaluation of the Pharmacokinetics, Bioequivalence, and Safety of Two Preparations of 20‐mg Trimetazidine in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2025;14(11):889-896. doi:10.1002/cpdd.1582
BibTeX
@article{Tan2025,
author = {Tan, Dongmei and Zhang, Fucai and Fu, Xihua and Su, Jianfen and Xu, Zuoheng and Yang, Hui and Mu, Yanping},
title = {Evaluation of the Pharmacokinetics, Bioequivalence, and Safety of Two Preparations of 20‐mg Trimetazidine in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
volume = {14},
number = {11},
pages = {889--896},
doi = {10.1002/cpdd.1582}
}
EUVIMED